Navigation Links
Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
Date:10/6/2010

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California. Lorcaserin, which Arena discovered and developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

"Obesity 2010 is an excellent scientific forum to present results from our recently completed clinical study evaluating the effects of lorcaserin on appetite, energy intake and energy expenditure," stated William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "We look forward to presenting at this event, and to lorcaserin's October 22nd PDUFA date."

The meeting schedule includes presentations of a lorcaserin mechanism of action study conducted by Drs. Eric Ravussin, Leanne Redman, Corby Martin and Steven Smith at the Pennington Biomedical Research Center in Baton Rouge, Louisiana.

Saturday, October 9, 2010

  • Oral Abstract Presentation: Lorcaserin, a Novel 5-HT2C Receptor Agonist, Causes Weight Loss Without Stimulating Energy Expenditure
  • Session Time:  4:45 p.m. - 6:15 p.m. Pacific Time (PT)

  • Sunday, October 10, 2010

  • Poster Presentation: Lorcaserin, a Selective 5-HT2C Receptor Agonist, Reduces Energy Intake and Appetite
  • Session Time: The poster will be on display from 9:30 a.m. to 1:45 p.m. PT and from 3:15 p.m. to 6:30 p.m. PT. Presenters will be available to discuss the poster from 12:30 p.m. to 1:30 p.m. PT.

  • About LorcaserinLorcaserin is a new chemical entity that is
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    2. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    3. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    4. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    5. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    7. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    8. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    9. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
    10. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
    11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... ROSEVILLE, Minn. , Sept. 17, 2014  Rebiotix Inc. ... of the company,s lead product candidate, RBX2660 (microbiota suspension) will ... the IDWeek 2014 conference in Philadelphia ... will be presented during the poster session on Thursday, October ... C. difficile Infection: 60-Day Interim Analysis of the ...
    (Date:9/17/2014)... DALLAS , Sept. 17, 2014   OTEMR, ... 2014 Edition Complete EHR certification, which designates that the ... the Stage 1 and Stage 2 Meaningful Use measures ... and Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
    (Date:9/17/2014)... of people suffer from neck and arm pain as a ... FDA approved the launch of a clinical trial for the ... Spinal Kinetics, which may offer relief to people with cervical ... for Special Surgery (HSS), the number one orthopedic hospital in ... York City and in the Northeast participating in ...
    Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2
    (Date:9/17/2014)... Thompson HealthDay Reporter ... the womb to household chemicals known as phthalates might ... University researchers reported in a new study. Children ... asthma between age 5 and 11 if their mothers ... phthalates (pronounced thal-ates), the researchers found. The two phthalates ...
    (Date:9/17/2014)... R.I. [Brown University] As Congress adjourns this month ... senators will step over on their way out the ... Repeal and Medicare Provider Payment Modernization Act of 2014. ... Surgery , Dr. Eli Adashi recounts what he and ... bipartisan bill. The perennial trouble with how Medicare pays ...
    (Date:9/17/2014)... Boston Children’s Museum and From ... concert series, introducing young Museum visitors to musicians ... premier national platform celebrating the stories, talents, and ... young musicians featured will also be showcased on ... is fortunate to partner with the wonderful musicians ...
    (Date:9/17/2014)... 2014 StartX , a nonprofit ... raising rounds of funding at its Summer Demo Day ... and media, was the first such gathering held at ... the university. The presentations were delivered on an expansive ... Labs, a 2,000 square foot life science facility that ...
    (Date:9/17/2014)... 17, 2014 The in vitro diagnostics ... technology market, focusing on molecular diagnostics for conditions such ... genetic testing. The IVD market value is projected to ... of 2017. The major drivers of the market’s growth ... which is evidenced by the explosion for raid and ...
    Breaking Medicine News(10 mins):Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
    ... Simon J. ... NJHCFFA. , ... --Simon J. Samaha, M.D., recently was confirmed by the New Jersey State Senate as one of ... (The Authority). , , , , ,Dr. Samaha is the President and Chief Executive Officer of ...
    ... Perkins Warns Houston "Abortion Super Center" Will Be Prototype ... Jan. 18 An estimated 10,000 people converged on ... across from the nation,s largest abortion facility.  Tony Perkins, president of ... Call to Conscience in Houston today to rally pro-life ...
    ... to ask simple question of male patients , MONDAY, ... strong warning sign that a man might be at ... problems, a long-running study indicates. , "We saw that ... men with erectile function still had a 40 percent ...
    ... experts stress that ,senior moments, don,t guarantee that dementia ... News) -- Mental lapses among older adults occur more ... new research finds. , Excessive daytime sleepiness, staring into ... fluctuations that often precede Alzheimer,s, say researchers from Washington ...
    ... 18 An urgent aid shipment containing 4,000 tents and ... Haitian coastal town of Jacmel. , Jacmel, 30 miles southwest of ... devastated by the recent earthquake with more than 350 people reported ... that 60 percent of buildings were damaged or destroyed. , An ...
    ... to Run in Honor of People With Cystic Fibrosis , ... Fibrosis Foundation,s most active volunteers will carry the Olympic Torch today in ... Opening Ceremony of the 2010 Olympic Winter Games. , Liz Burns ... than $600,000 for CF research, care and education programs. She is ...
    Cached Medicine News:Health News:Simon J. Samaha, M.D., Appointed Public Member of New Jersey Health Care Facilities Financing Authority 2Health News:FRC's Tony Perkins Speaks to Rally of Ten Thousand Across from Nation's Largest Abortion Facility 2Health News:Erectile Dysfunction Predicts Heart Disease 2Health News:Frequent Mental Lapses May Precede Alzheimer's 2Health News:Frequent Mental Lapses May Precede Alzheimer's 3Health News:Haiti: Lifesaving Aid Makes Its Way Through to Quake-Hit Jacmel by Ship 2Health News:Cystic Fibrosis Foundation Volunteer to Carry Torch for Vancouver 2010 Olympic Winter Games 2
    The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
    Provides exceptional resolution and fundus scanning capability. Excellent for small pupil diagnosis and treatment....
    The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
    ... MK-2000 Keratome System provides ... wide range of applications. ... ultra-sharp stainless steel disposable ... sterile and ready to ...
    Medicine Products: